Why Are Curis (NASDAQ:CRIS) Stocks Soaring In Markets Today?

2 min read | December 08, 2020 08:51 AM PST | By Kunal Sawhney

Why Are Curis (NASDAQ:CRIS) Stocks Soaring In Markets Today?

Curis Study Results

In an official statement, the biotechnology firm claimed that its Phase 1 dose escalation study of CA-4948 among AML and MDS patients produced positive results.

The CA-4948 targets a small molecule -- IRAK4 kinase inhibitor, which acts like a toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. The therapy caused consistent reduction of marrow blast reductions in trial patients.

Curis Stock Performance & Financial Outlook

The biotech stock has sprinted by over 459 per cent in the last one month and gained 388 per cent in last six months. Its current price to cash flow ratio is 36.4, while return on equity is 113.5 per cent, as per TMX data. However, the stock holds a negative return on assets of 70.49 per cent.

Its current market cap is $371 million.

The company’s quarterly revenue (for the period ending September 30, 2020) was $2.7 million while gross profit was $2.6 million. Cash and cash equivalents as of November 30, 2020, stood at $26.3 million.

The company is also developing CI-8993, for treatment of cancers driven by VISTA-mediated Immune Suppression via both monotherapy and combination therapy.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.